keyword
MENU ▼
Read by QxMD icon Read
search

duloxetine pain

keyword
https://www.readbyqxmd.com/read/29354587/botulinum-toxin-type-a-injection-for-neuropathic-pain-in-a-patient-with-a-brain-tumor-a-case-report
#1
Kyung Eun Nam, Joon Sung Kim, Bo Young Hong, Bomi Sul, Hyehoon Choi, So Yeon Jun, Seong Hoon Lim
Neuropathic pain is usually managed pharmacologically, rather than with botulinum toxin type A (BTX-A). However, medications commonly fail to relieve pain effectively or have intolerable side effects. We present the case of a 62-year-old man diagnosed with an intracranial chondrosarcoma, which was removed surgically and treated with radiation therapy. He suffered from neuropathic pain despite combined pharmacological therapy with gabapentin, amitriptyline, tramadol, diazepam, and duloxetine because of adverse effects...
December 2017: Annals of Rehabilitation Medicine
https://www.readbyqxmd.com/read/29343477/role-of-asic3-nav1-7-and-nav1-8-in-electroacupuncture-induced-analgesia-in-a-mouse-model-of-fibromyalgia-pain
#2
Liang-Ta Yen, Yu-Chan Hsu, Jaung-Geng Lin, Ching-Liang Hsieh, Yi-Wen Lin
BACKGROUND: The mechanisms underlying fibromyalgia (FM) pain are not understood. The US Food and Drug Administration has recommended three drugs for treating FM-namely, pregabalin, duloxetine and milnacipran; however, these medications are associated with severe side effects. OBJECTIVE: To create a mouse model of FM pain using dual injections of acidic saline to cause mechanical hyperalgesia and test whether ASIC3, Nav1.7 and Nav1.8 are involved in this process and whether electroacupuncture (EA) can reverse these phenomena...
January 17, 2018: Acupuncture in Medicine: Journal of the British Medical Acupuncture Society
https://www.readbyqxmd.com/read/29238391/functional-impairment-and-painful-physical-symptoms-in-patients-with-major-depressive-disorder-treated-with-antidepressants-real-world-evidence-from-the-middle-east
#3
Jihyung Hong, Diego Novick, Maria Victoria Moneta, Ahmed El-Shafei, Héctor Dueñas, Josep Maria Haro
Background: The Global Burden of Disease 2010 study reported the relative size of major depressive disorder (MDD) burden to be greater in the Middle East and North Africa than anywhere else. However, little research has been carried out to examine the comparative effectiveness of antidepressants in this region. Objective: To assess and compare functioning levels in Middle Eastern patients with MDD treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI), and to examine the impacts of depression-related pain on functioning by the type of treatment...
2017: Clinical Practice and Epidemiology in Mental Health: CP & EMH
https://www.readbyqxmd.com/read/29228247/a-randomized-double-blind-placebo-and-active-comparator-controlled-phase-i-study-of-analgesic-antihyperalgesic-properties-of-asp8477-a-fatty-acid-amide-hydrolase-inhibitor-in-healthy-female-subjects
#4
Klaus Schaffler, Ashraf Yassen, Peter Reeh, Paul Passier
Objectives: To evaluate the analgesic/antihyperalgesic effect of ASP8477. Design: Randomized, double-blind, double-dummy, cross-over, placebo- and active comparator-controlled study. Setting: HPR Dr. Schaffler GmbH, Munich, Germany. Subjects: Healthy female subjects aged 18-65 years. Methods: Eligible subjects were randomly assigned to one of six treatment sequences and received multiple ascending doses of ASP8477, duloxetine, and placebo over three treatment periods (each consisting of 21-day dosing separated by 14-day washout periods)...
December 8, 2017: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/29206213/duloxetine-protects-against-oxaliplatin-induced-neuropathic-pain-and-spinal-neuron-hyperexcitability-in-rodents
#5
Woojin Kim, Yeongu Chung, Seunghwan Choi, Byung-Il Min, Sun Kwang Kim
Oxaliplatin is a widely used chemotherapy agent, but induces serious peripheral neuropathy. Duloxetine is a dual reuptake inhibitor of serotonin and norepinephrine, and is shown to be effective against pain. However, whether and how duloxetine can attenuate oxaliplatin-induced allodynia in rodents is not clearly understood. A single injection of oxaliplatin (6 mg/kg, intraperitoneal; i.p.) induced a cold and mechanical allodynia, which was assessed by acetone and von Frey filament tests, respectively. When significant allodynic signs were observed, three different doses of duloxetine (10, 30, and 60 mg/kg, i...
December 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29197345/perioperative-duloxetine-and-etoricoxibto-improve-postoperative-pain-after-lumbar-laminectomy-a-randomized-double-blind-controlled-study
#6
Josef Zekry Attia, Haidy Salah Mansour
BACKGROUND: Duloxetine, Etoricoxib and opioid are of the commonly administered drugs in Lumbar laminectomy. The aim of this study is to assess the effect of perioperative use of Duloxetine in combination with Etoricoxib on postoperative pain and opioid requirements. METHODS: One hundred twenty patients with ASA physical status were enrolled with age between 18 and 70 years. Patients were divided randomly into four groups of 30 patients: group P received placebo, group E received etoricoxib 120 mg, group D received duloxetine 60 mg and group D/E received duloxetine 60 mg capsules and etoricoxib 120 mg; 1 h before surgery and 24 h after...
December 2, 2017: BMC Anesthesiology
https://www.readbyqxmd.com/read/29170185/dysosmia-and-dysgeusia-associated-with-duloxetine
#7
Katsuyuki Yoshida, Takahiko Fukuchi, Hitoshi Sugawara
Common adverse effects of serotonin-norepinephrine reuptake inhibitors are nausea, dry mouth, dizziness and headache. We describe the case of a patient with dysosmia and subsequent dysgeusia associated with duloxetine. A 68-year-old Japanese woman with a history of type 1 diabetes mellitus, hypertension, insomnia and reflux esophagitis presented to a local hospital with bilateral leg pain; she was treated with duloxetine. However, after 4 weeks, she sensed rotten egg smell, experienced nausea and vomiting and was admitted to our hospital...
November 23, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29142460/efficacy-and-safety-of-duloxetine-in-chinese-breast-cancer-patients-with-paclitaxel-induced-peripheral-neuropathy
#8
Jiani Wang, Qing Li, Binghe Xu, Tongtong Zhang, Shanshan Chen, Yang Luo
Objective: Chemotherapy with paclitaxel is associated with significant neurotoxicity that may offset patients' quality of life and therapeutic benefits. This prospective, non-randomized control study evaluated the efficacy and safety of an antidepressant drug, duloxetine, at 30 or 60 mg/d, in the treatment of paclitaxel-induced peripheral neuropathy (PIPN) in Chinese breast cancer patients. Methods: A total of 102 patients with a median age of 50 (range, 25-60) years, treated in the Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, between November 2014 and January 2017 were finally enrolled...
October 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/29136387/randomized-multicenter-placebo-controlled-clinical-trial-of-duloxetine-versus-placebo-for-aromatase-inhibitor-associated-arthralgias-in-early-stage-breast-cancer-swog-s1202
#9
N Lynn Henry, Joseph M Unger, Anne F Schott, Louis Fehrenbacher, Patrick J Flynn, Debra M Prow, Carl W Sharer, Gary V Burton, Charles S Kuzma, Anna Moseley, Danika L Lew, Michael J Fisch, Carol M Moinpour, Dawn L Hershman, James L Wade
Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and Drug Administration approved for treatment of multiple chronic pain disorders. We hypothesized that treatment of AIMSS with duloxetine would improve average joint pain compared with placebo. Methods This randomized, double-blind, phase III trial included AI-treated postmenopausal women with early-stage breast cancer and who had average joint pain score of ≥ 4 out of 10 that developed or worsened since AI therapy initiation...
November 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29121279/clinical-and-preclinical-perspectives-on-chemotherapy-induced-peripheral-neuropathy-cipn-a-narrative-review
#10
S J L Flatters, P M Dougherty, L A Colvin
This review provides an update on the current clinical and preclinical understanding of chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome includes a review of its assessment, diagnosis and treatment. CIPN is caused by several widely-used chemotherapeutics including paclitaxel, oxaliplatin, bortezomib. Severe CIPN may require dose reduction, or cessation, of chemotherapy, impacting on patient survival. While CIPN often resolves after chemotherapy, around 30% of patients will have persistent problems, impacting on function and quality of life...
October 1, 2017: British Journal of Anaesthesia
https://www.readbyqxmd.com/read/29066930/the-effect-of-pregabalin-or-duloxetine-on-arthritis-pain-a-clinical-and-mechanistic-study-in-people-with-hand-osteoarthritis
#11
Nidhi Sofat, Abiola Harrison, Mark D Russell, Salma Ayis, Patrick D Kiely, Emma H Baker, Thomas Richard Barrick, Franklyn A Howe
Osteoarthritis (OA) is the most prevalent arthritis worldwide and is characterized by chronic pain and impaired physical function. We hypothesized that heightened pain in hand OA could be reduced with duloxetine or pregabalin. In this prospective, randomized clinical study, we recruited 65 participants, aged 40-75 years, with a Numerical Rating Scale (NRS) for pain of at least 5. Participants were randomized to one of the following three groups: duloxetine, pregabalin, and placebo. The primary endpoint was the NRS pain score, and the secondary endpoints included the Australian and Canadian Hand Osteoarthritis Index (AUSCAN) pain, stiffness, and function scores and quantitative sensory testing by pain pressure algometry...
2017: Journal of Pain Research
https://www.readbyqxmd.com/read/29053665/is-duloxetine-an-alternative-in-the-treatment-of-osteoarthritis
#12
Joaquín Ananías, Sebastián Irarrázaval
INTRODUCTION: Many osteoarthritis patients continue to present symptoms despite nonsurgical treatment. Duloxetine might be a viable alternative for such cases, but real clinical relevance remains unclear. METHODS: A literature review was conducted in Epistemonikos, the largest database for systematic reviews in health that compiles multiple sources, including MEDLINE, EMBASE, and Cochrane, among others. Relevant data were extracted, and information from the primary studies was reanalyzed...
October 18, 2017: Medwave
https://www.readbyqxmd.com/read/29044171/pharmacological-sensitivity-of-reflexive-and-nonreflexive-outcomes-as-a-correlate-of-the-sensory-and-affective-responses-to-visceral-pain-in-mice
#13
Beatriz de la Puente, Daniel Zamanillo, Luz Romero, José M Vela, Manuel Merlos, Enrique Portillo-Salido
Pain encompasses both sensory and affective dimensions which can be differentially modulated by drugs. Here, we compare the pharmacological sensitivity of the sensory and affective responses using acetic acid-induced abdominal writhings (sensory-reflexive outcome) and acetic acid-induced depression of reward seeking behaviour (RSB, affective-nonreflexive outcome) to a highly palatable food in mice. We found that the expression of RSB critically depends on factors such as sex and previous knowledge and type of the food stimulus...
October 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29042779/comparison-of-duloxetine-and-ssri-as-a-treatment-option-of-painful-physical-symptoms-associated-with-major-depressive-disorder
#14
COMMENT
Miqdad Haider, Muhammad Nabeel Shafqat
No abstract text is available yet for this article.
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29026967/a-rat-model-of-folfox-induced-neuropathy-effects-of-oral-dimiracetam-in-comparison-with-duloxetine-and-pregabalin
#15
Lorenzo Di Cesare Mannelli, Mario Maresca, Laura Micheli, Carlo Farina, Michael W Scherz, Carla Ghelardini
BACKGROUND AND AIM: The FOLFOX family of chemotherapy regimens are hampered by the development of a painful neuropathy. Current clinical treatments are inadequate, and furthermore, the research of innovative drugs is strongly disadvantaged by the absence of a preclinical model based on the complete mixture of FOLFOX components. The aim of this study was to set up a rat model of FOLFOX-induced neuropathy in rats, validate its predictability by reference drugs, and evaluate the effectiveness of the new anti-neuropathic compound dimiracetam...
October 12, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29026309/predicting-treatment-outcomes-of-major-depressive-disorder-by-early-improvement-in-painful-physical-symptoms-a-pooled-analysis-of-double-blind-placebo-controlled-trials-of-duloxetine
#16
Hirofumi Tokuoka, Makoto Nishihara, Shinji Fujikoshi, Aki Yoshikawa, Atsushi Kuga
OBJECTIVE: We determined if early improvement in painful physical symptoms (PPS) can be a predictor of remission in the treatment of major depressive disorder (MDD). METHODS: We included randomized, double-blind, parallel-group clinical trials of duloxetine (40-60 mg/day) versus placebo for the acute treatment of MDD with associated PPS. Only those studies using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Brief Pain Inventory - Short Form (BPI-SF) were included...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28984402/efficacy-acceptability-and-safety-of-cognitive-behavioural-therapies-in-fibromyalgia-syndrome-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#17
REVIEW
K Bernardy, P Klose, P Welsch, W Häuser
This updated systematic review aimed at evaluating the efficacy, acceptability and safety of cognitive behavioural therapies (CBTs) in fibromyalgia syndrome (FMS). Clinicaltrials.gov, Cochrane Library, MEDLINE, PsycINFO and SCOPUS were searched from September 2013 to May 2017. Randomized controlled trials (RCTs) comparing CBTs with controls were analysed. Primary outcomes were ≥50% pain relief, ≥20% improvement of health-related quality of life (HRQoL), negative mood, fatigue, disability, acceptability and safety at end of therapy and at 6 months follow-up...
October 6, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/28953050/repeated-administration-of-amitriptyline-in-neuropathic-pain-modulation-of-the-noradrenergic-descending-inhibitory-system
#18
Tadanao Hiroki, Takashi Suto, Shigeru Saito, Hideaki Obata
BACKGROUND: The tricyclic antidepressant amitriptyline, the serotonin and noradrenaline reuptake inhibitor duloxetine, and gabapentinoids are first-line drugs for treatment of neuropathic pain. The analgesic effect of these drugs relates to brainstem-spinal descending noradrenergic systems. However, amitriptyline utilizes a variety of mechanisms for analgesia in neuropathic pain, and it is unclear which mechanism is most important. In the present study, we investigated the role of descending noradrenergic systems in the analgesic effect of these drugs for treatment of neuropathic pain...
August 4, 2017: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/28952182/effects-of-duloxetine-on-pain-and-walking-distance-in-neuropathic-pain-models-via-modulation-of-the-spinal-monoamine-system
#19
K Minami, R Tamano, E Kasai, H Oyama, M Hasegawa, S Shinohara, T Asaki
BACKGROUND: Approximately 40% of patients with chronic low back pain have a neuropathic component. In this study, we assessed the effects of analgesics on tactile hypersensitivity and walking distance in the rat cauda equina compression (CEC) model of neuropathic low back pain. METHODS: The effects of analgesics on tactile hypersensitivity were examined using the von Frey test in CEC and partial sciatic nerve ligation (pSNL) models. Effects on walking distance were assessed using a treadmill test...
September 26, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/28919811/response-to-duloxetine-in-chronic-low-back-pain-exploratory-post-hoc-analysis-of-a-japanese-phase-iii-randomized-study
#20
Toshinaga Tsuji, Naohiro Itoh, Mitsuhiro Ishida, Toshimitsu Ochiai, Shinichi Konno
PURPOSE: Duloxetine is efficacious for chronic low back pain (CLBP). This post hoc analysis of a Japanese randomized, placebo-controlled trial (ClinicalTrials.gov, NCT01855919) assessed whether patients with CLBP with early pain reduction or treatment-related adverse events of special interest (TR-AESIs; nausea, somnolence, constipation) have enhanced responses to duloxetine. PATIENTS AND METHODS: Patients (N = 456) with CLBP for ≥6 months and Brief Pain Inventory (BPI) average pain severity score of ≥4 were randomized (1:1) to duloxetine 60 mg/day or placebo for 14 weeks...
2017: Journal of Pain Research
keyword
keyword
75047
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"